Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity.
about
Advances in targeting signal transduction pathwaysPhospho-ΔNp63α/miR-885-3p axis in tumor cell life and cell death upon cisplatin exposure.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Targeting nucleocytoplasmic transport in cancer therapyInvolvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapyCooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.Re-oxygenation causes hypoxic tumor regression through restoration of p53 wild-type conformation and post-translational modificationsTissue-specific expression of p73 C-terminal isoforms in mice.Recent discoveries in the cycling, growing and aging of the p53 fieldCommon drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a.Cyclotherapy: opening a therapeutic window in cancer treatment.Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
P2860
Q27686983-2C11224F-C4D9-40C5-B467-D8B86249C3BAQ34231282-CAD4D7EE-110C-4250-B36F-9FC7D6535B6BQ34307356-C2374EB8-A33C-4326-B647-64208BB92E21Q34398166-1D171BE6-1390-4D4D-89C7-97F4A5D3F730Q35640228-F747C555-779B-46F1-88FB-74B8AF1B665BQ35640301-BDF851E9-0C81-4793-B248-0A740920A686Q35865264-97367877-08BD-4D23-9477-3B77919ACF52Q36556362-8D235BD4-130F-4DE4-83D0-94615A50AB6DQ36736358-16130AE1-4D72-4A6D-A8CE-00E4D25FFC1DQ36926148-F2481C3D-12A1-4EAC-9677-24B5965AB3A3Q39237016-6C8246EC-D2E2-49DE-835F-CDEEAB39C18AQ39328413-FB33106C-EAE2-4938-80D9-52E4A3A7CC15Q39328882-8FFBF5AC-9A84-41D0-9C77-6A5F0EA671A7Q41866750-7AB43DA2-15C0-446E-8DCC-541B3D781E19
P2860
Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Exploiting p53 status to enhan ...... lowering associated toxicity.
@ast
Exploiting p53 status to enhan ...... lowering associated toxicity.
@en
type
label
Exploiting p53 status to enhan ...... lowering associated toxicity.
@ast
Exploiting p53 status to enhan ...... lowering associated toxicity.
@en
prefLabel
Exploiting p53 status to enhan ...... lowering associated toxicity.
@ast
Exploiting p53 status to enhan ...... lowering associated toxicity.
@en
P2093
P2860
P356
P1433
P1476
Exploiting p53 status to enhan ...... lowering associated toxicity.
@en
P2093
Alberto M Martelli
Ferdinando Nicoletti
James A McCubrey
Linda S Steelman
P2860
P304
P356
10.18632/ONCOTARGET.247
P407
P577
2011-03-01T00:00:00Z